DIA
HRMY icon

Dana Investment Advisors’s Harmony Biosciences HRMY Stock Holding History

Dana Investment Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,402
Closed -$372K – 402
2023
Q1 		$372K Buy
+11,402
New +$519K 0.02% 342

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Dana Investment Advisors's HRMY Position: Q2 2023 in Review

Dana Investment Advisors sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 11,402 shares — an estimated $372K sold.

Dana Investment Advisors first reported a position in HRMY in Q1 2023 and held it in 1 quarter. The position peaked at $372K in Q1 2023. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Dana Investment Advisors reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Dana Investment Advisors sold 11,402 Harmony Biosciences shares in Q2 2023, an estimated $372K.
  • Dana Investment Advisors first reported a position in Harmony Biosciences in Q1 2023 and held it in 1 quarter.
  • Dana Investment Advisors's Harmony Biosciences position peaked at $372K in Q1 2023.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Dana Investment Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.